15. Remicade

Remicade's most recent biosimilar challenger was approved in December. (Johnson & Johnson)

Company: Johnson & Johnson
2019 sales: $5.03 billion
Projected 2026 sales: $1.39 billion
Projected CAGR: -17%
Used for: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease

Once a giant in the immunology field, sales of Johnson & Johnson's Remicade have slipped precipitously after years of biosimilar competition. The future doesn't look much brighter, unfortunately, and J&J is looking for winners in its portfolio to make up the gap. 

Remicade hit $5.03 billion in sales in 2019, and it could see a catastrophic 17% decline in sales through 2026, according to Evaluate Pharma. That forecast would put Remicade's 2026 sales at roughly $1.36 billion. 

The wheels have already come off Remicade's sales after more than two years of biosimilar pressure. In the second quarter, the drug's sales dipped by 14% from the same period last year at $935 million. 

RELATED: Bolstered by immunology and oncology, J&J's pharma business holds up under COVID-19 pressure

15. Remicade

Suggested Articles

The next wave of immuno-oncology R&D includes drugs that interact with a wide range of emerging immune targets, including TIGIT and CD47.

Emerging targets like KRAS, MET and RET are inspiring novel kinase inhibitor development and fueling billions in pharma deals.

Despite the rise of cell therapies to treat cancer, R&D centered on novel tyrosine kinase inhibitors and immuno-oncology targets is booming.